Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Omeros Corporation - Common Stock (NQ:OMER)

4.125 -0.055 (-1.32%)
Streaming Delayed Price Updated: 10:55 AM EDT, Sep 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Omeros Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Omeros Announces Publication Highlighting Survival Outcomes in TA-TMA Patients Treated with Narsoplimab Under Its Global Expanded Access Program
From Omeros Corporation
Via Business Wire
Omeros Posts 2,652 Percent Sales Jump
Via The Motley Fool
Omeros Corp (NASDAQ:OMER) Reports Q2 2025: Narrowed Losses, Regulatory Progress, and Market Optimism
Omeros Corp (OMER) reports Q2 2025 with narrowed losses, progress on narsoplimab FDA approval, and strategic debt restructuring. Shares rise on regulatory optimism. 
Via Chartmill
Omeros Corporation Reports Second Quarter 2025 Financial Results
From Omeros Corporation
Via Business Wire
Earnings Scheduled For August 14, 2025
 
Via Benzinga
Earnings Preview: Omeros
 
Via Benzinga
Examining the Future: Omeros's Earnings Outlook
 
Via Benzinga
Omeros Corporation to Announce Second Quarter Financial Results on August 14, 2025
From Omeros Corporation
Via Business Wire
InvestorNewsBreaks – D. Boral Capital LLC Acts as Exclusive Placement Agent for $22 Million Omeros (NASDAQ: OMER) Offering
Via Investor Brand Network
D. Boral Capital Acted as Exclusive Placement Agent to Omeros Corporation (Nasdaq: OMER) in Connection with its $22,000,000 Registered Direct Offering
Via ACCESS Newswire
Omeros Corporation Announces Pricing of $22 Million Registered Direct Offering
From Omeros Corporation
Via Business Wire
Omeros Seeks EMA Approval For Narsoplimab After Data Shows 3X Survival Boost
The application includes outcomes from more than 130 patients treated under an expanded access program, supporting broader regulatory momentum for narsoplimab. 
Via Stocktwits
Omeros Submits Narsoplimab Marketing Authorization Application to the European Medicines Agency for the Treatment of TA-TMA
From Omeros Corporation
Via Business Wire
Omeros Announces Webcast Details for Annual Meeting of Shareholders
From Omeros Corporation
Via Business Wire
Omeros Analyst Sees $1 Billion Potential For Narsoplimab Before FDA Decision
H.C. Wainwright's Brandon Folkes initiated Omeros with a Buy. 
Via Benzinga
This Domino's Pizza Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Tuesday
 
Via Benzinga
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Quarter
 
Via Benzinga
Omeros Corporation Reports First Quarter 2025 Financial Results
From Omeros Corporation
Via Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
Earnings Scheduled For May 15, 2025
 
Via Benzinga
Omeros Corporation to Announce First Quarter Financial Results on May 15, 2025
From Omeros Corporation
Via Business Wire
Top movers analysis one hour before the close of the markets on 2025-05-12: top gainers and losers in today's session.
Curious to know what's happening on the US markets one hour before the close of the markets on Monday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
Which stocks are moving on Monday?
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements. 
Via Chartmill
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
These stocks are gapping in today's session
In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down. 
Via Chartmill
Omeros Corporation Announces Agreements to Acquire $80.5 Million of its Convertible Senior Notes Due 2026
From Omeros Corporation
Via Business Wire
FDA Accepts Resubmission of BLA for Narsoplimab for Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (TA-TMA) and Assigns Late September PDUFA Date
From Omeros Corporation
Via Business Wire
Eagle Financial Services, Nvidia And Other Big Stocks Moving Lower In Monday's Pre-Market Session
 
Via Benzinga
Omeros' New Leukemia Drug Team Ignites Hope For Cancer Fight
Omeros forms oncology committee to guide development of its AML therapy, which showed strong efficacy and safety in preclinical studies targeting leukemia cells. 
Via Benzinga
Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros’ Proprietary OncotoX-AML Clinical Program
From Omeros Corporation
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.